Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Asmanex
2. Asmanex Twisthaler
3. Elocon
4. Furoate Monohydrate, Mometasone
5. Furoate, Mometasone
6. Mometasone
7. Mometasone Furoate Monohydrate
8. Monohydrate, Mometasone Furoate
9. Nasonex
10. Rinelon
11. Sch 32088
12. Sch-32088
13. Sch32088
14. Twisthaler, Asmanex
1. 83919-23-7
2. Asmanex
3. Nasonex
4. Elocon
5. Monovo
6. Sch 32088
7. Mometasone 17-furoate
8. Sinuva
9. Mometasone Furoate Anhydrous
10. Sch32088
11. Sch-32088
12. Nsc-746171
13. Chembl1161
14. Lyr210
15. (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Furan-2-carboxylate
16. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
17. Chebi:47564
18. Lyr-210
19. 04201gdn4r
20. Nsc-760077
21. (11beta,16alpha)-9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
22. Danitin
23. Ecural
24. Elomet
25. Dsstox_cid_3333
26. Asmanex Twisthaler
27. Dsstox_rid_76981
28. Dsstox_gsid_23333
29. (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
30. 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
31. Elocone
32. Flumeta
33. Nosorex
34. Rimelon
35. Ovixan
36. Asmanex Hfa
37. Mometasone Fuorate
38. Mof
39. Unii-04201gdn4r
40. Mometasone-furoate
41. Ncgc00016950-01
42. Prestwick_924
43. Asmanex (tn)
44. Mometasone Furoate [usan:usp:jan]
45. Cas-83919-23-7
46. Elocon (tn)
47. Las 41002
48. Brn 4340538
49. Prestwick0_000572
50. Prestwick1_000572
51. Prestwick2_000572
52. Prestwick3_000572
53. Mometasone Furancarboxylate
54. Schembl4568
55. Bspbio_000384
56. Mometasone 17-(2-furoate)
57. Mls002153879
58. Spbio_002603
59. Mometasone Furoate (jan/usp)
60. Bpbio1_000424
61. Mometasone Furoate [mi]
62. Dtxsid4023333
63. Mometasone Furoate [jan]
64. Mometasone Furoate [usan]
65. Hms1569d06
66. Hms2096d06
67. Hms2235i14
68. Hms3713d06
69. Mometasone Furoate [vandf]
70. Mometasone Furoate [mart.]
71. Mometasone Furoate [usp-rs]
72. Mometasone Furoate [who-dd]
73. Zinc3938677
74. Tox21_110705
75. Ac-941
76. Bdbm50148733
77. Mfcd00866003
78. Nsc746171
79. S1987
80. Mometasone Furoate, >=98% (hplc)
81. Akos015994732
82. Tox21_110705_1
83. Ccg-220572
84. Db14512
85. Ks-1275
86. Mometasone Furoate [green Book]
87. Nsc 746171
88. Nsc 760077
89. 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
90. Mometasone Furoate [orange Book]
91. Mometasone Furoate [ep Monograph]
92. Ncgc00179578-01
93. Ncgc00179578-03
94. Ncgc00179578-04
95. (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
96. Dulera Component Mometasone Furoate
97. Hy-13693
98. Mometasone Furoate [usp Monograph]
99. Smr001233233
100. M2354
101. Mometasone Furoate Component Of Dulera
102. C07817
103. D00690
104. Mometasone Furoate 1000 Microg/ml In Methanol
105. 919m237
106. A840685
107. Mometasone Furoate 100 Microg/ml In Acetonitrile
108. Sr-01000841209
109. Lyr-220 Active Component Mometasone Furoate
110. Q-101380
111. Q1044248
112. Sr-01000841209-2
113. Brd-k60640630-001-03-7
114. Brd-k60640630-001-11-0
115. Mometasone Furoate, European Pharmacopoeia (ep) Reference Standard
116. Mometasone Furoate, United States Pharmacopeia (usp) Reference Standard
117. 11?,16?)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
118. Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material
119. (11.beta.,16.alpha.)-9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
120. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate;mometasone Furoate
121. [(9r,10s,11s,13s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
122. 9,21-dichloro-11.beta.,17-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
123. Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
124. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)
125. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
| Molecular Weight | 521.4 g/mol |
|---|---|
| Molecular Formula | C27H30Cl2O6 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 520.1419441 g/mol |
| Monoisotopic Mass | 520.1419441 g/mol |
| Topological Polar Surface Area | 93.8 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 1020 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 2 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 3 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 5 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 6 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients 4 years. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients 2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients 2 years, treating nasal polyps in patients 18 years, and prophylaxis of seasonal allergic rhinitis in patients 12 years. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients 2 years.
FDA Label
Seasonal and perennial allergic rhinitis
Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Absorption
The mean time to peak concentration is 1.0 to 2.5 hours. Bioavailability has been reported as <1% but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%. The 0.1% ointment may have a bioavailability of 0.7%.
Route of Elimination
For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine.
Volume of Distribution
Steady state volume of distribution of 152L.
Clearance
The clearance rate of mometasone furoate is not readily available, though it may be close to 90L/h.
Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate.
The terminal half life of an inhaled dose is approximately 5 hours though it has been reported as 5.8 hours by other sources.
In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes. There is also evidence of inhibition of histamine, leukotrienes, and cytokines. Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of [dexamethasone]. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5). Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB).
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - OINTMENT;TOPICAL - 0.1%
USFDA APPLICATION NUMBER - 19543
DOSAGE - CREAM;TOPICAL - 0.1% **Federal Regis...DOSAGE - CREAM;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19625
DOSAGE - LOTION;TOPICAL - 0.1% **Federal Regi...DOSAGE - LOTION;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19796
DOSAGE - AEROSOL, METERED;INHALATION - 0.05MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.05MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - AEROSOL, METERED;INHALATION - 0.10MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.10MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - AEROSOL, METERED;INHALATION - 0.20MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.20MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY ...DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20762
DOSAGE - POWDER;INHALATION - 0.11MG/INH
USFDA APPLICATION NUMBER - 21067
DOSAGE - POWDER;INHALATION - 0.22MG/INH
USFDA APPLICATION NUMBER - 21067
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH
USFDA APPLICATION NUMBER - 22518
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH
USFDA APPLICATION NUMBER - 22518
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH
USFDA APPLICATION NUMBER - 22518
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Solubilizers
Fillers, Diluents & Binders
Thickeners and Stabilizers
Direct Compression
Parenteral
Co-Processed Excipients
Topical
Coating Systems & Additives
Film Formers & Plasticizers
Granulation
Rheology Modifiers
Emulsifying Agents
Disintegrants & Superdisintegrants
Controlled & Modified Release
Taste Masking
Surfactant & Foaming Agents
Coloring Agents
Chewable & Orodispersible Aids
Lubricants & Glidants
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
91
PharmaCompass offers a list of Mometasone Furoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mometasone Furoate manufacturer or Mometasone Furoate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mometasone Furoate manufacturer or Mometasone Furoate supplier.
PharmaCompass also assists you with knowing the Mometasone Furoate API Price utilized in the formulation of products. Mometasone Furoate API Price is not always fixed or binding as the Mometasone Furoate Price is obtained through a variety of data sources. The Mometasone Furoate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nasonex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nasonex, including repackagers and relabelers. The FDA regulates Nasonex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nasonex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nasonex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nasonex supplier is an individual or a company that provides Nasonex active pharmaceutical ingredient (API) or Nasonex finished formulations upon request. The Nasonex suppliers may include Nasonex API manufacturers, exporters, distributors and traders.
click here to find a list of Nasonex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nasonex DMF (Drug Master File) is a document detailing the whole manufacturing process of Nasonex active pharmaceutical ingredient (API) in detail. Different forms of Nasonex DMFs exist exist since differing nations have different regulations, such as Nasonex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nasonex DMF submitted to regulatory agencies in the US is known as a USDMF. Nasonex USDMF includes data on Nasonex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nasonex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nasonex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nasonex Drug Master File in Japan (Nasonex JDMF) empowers Nasonex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nasonex JDMF during the approval evaluation for pharmaceutical products. At the time of Nasonex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nasonex suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nasonex Drug Master File in Korea (Nasonex KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nasonex. The MFDS reviews the Nasonex KDMF as part of the drug registration process and uses the information provided in the Nasonex KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nasonex KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nasonex API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nasonex suppliers with KDMF on PharmaCompass.
A Nasonex CEP of the European Pharmacopoeia monograph is often referred to as a Nasonex Certificate of Suitability (COS). The purpose of a Nasonex CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nasonex EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nasonex to their clients by showing that a Nasonex CEP has been issued for it. The manufacturer submits a Nasonex CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nasonex CEP holder for the record. Additionally, the data presented in the Nasonex CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nasonex DMF.
A Nasonex CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nasonex CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nasonex suppliers with CEP (COS) on PharmaCompass.
A Nasonex written confirmation (Nasonex WC) is an official document issued by a regulatory agency to a Nasonex manufacturer, verifying that the manufacturing facility of a Nasonex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nasonex APIs or Nasonex finished pharmaceutical products to another nation, regulatory agencies frequently require a Nasonex WC (written confirmation) as part of the regulatory process.
click here to find a list of Nasonex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nasonex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nasonex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nasonex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nasonex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nasonex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nasonex suppliers with NDC on PharmaCompass.
Nasonex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nasonex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nasonex GMP manufacturer or Nasonex GMP API supplier for your needs.
A Nasonex CoA (Certificate of Analysis) is a formal document that attests to Nasonex's compliance with Nasonex specifications and serves as a tool for batch-level quality control.
Nasonex CoA mostly includes findings from lab analyses of a specific batch. For each Nasonex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nasonex may be tested according to a variety of international standards, such as European Pharmacopoeia (Nasonex EP), Nasonex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nasonex USP).
